MYRIAD GENETICS INC
No SEC Form 4 filings for $MYGN in the last 30 days.
Roblox (RBLX), Hertz (HTZ) and Myriad Genetics (MYGN) fell to 52-week lows as investors cited weaker outlooks and operational issues. RBLX dropped after Q2 revenue of $1.47B missed expectations and it withdrew its 2026 outlook. HTZ slid on margin pressure and $11.6B debt. MYGN sank after Q2 revenue of $190.7M missed and it cut its full-year forecast.
Simply Wall St reports Myriad Genetics (MYGN) shares are down 49% after the company cut its 2026 revenue outlook, citing weakness in prenatal testing. The piece references analyst fair value estimates and highlights potential positive and negative factors for investors, but provides no specific new financial figures beyond the outlook cut.
Simply Wall St reports Myriad Genetics (MYGN) shares fell nearly 47% in a day after results showed a revenue reset and loss fears. Q2 revenue was $190.7m, down 11% year over year, and full-year 2026 sales guidance was cut to $770m to $790m. Adjusted EBITDA guidance was suspended.
Over the past 7 days, alphai's AI scored 3 news stories mentioning MYGN (MYRIAD GENETICS INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 3 bearish.
Recent MYGN coverage spans earnings, market movers and technology.
Guidance reset and profitability target suspension materially worsened the outlook, supporting further de-risking.
Guidance cut tied to prenatal test weakness implies near-term demand softness and margin pressure risk.
The article frames a revenue reset driven by pricing and payer reimbursement pressure, with guidance suspension increasing downside uncertainty.
Guidance suspension plus ongoing reimbursement pressure increases downside risk to 2026 profitability while initiatives aim to stabilize collections and margins.
Operational efficiency gains in revenue cycle management could improve cash conversion and reduce labor costs, but the article provides no financial guidance.
alphai scores every news story that mentions MYGN with an AI model for sentiment and relevance, and aggregates insider trades from MYRIAD GENETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Roblox (RBLX), Hertz (HTZ) and Myriad Genetics (MYGN) fell to 52-week lows as investors cited weaker outlooks and operational issues. RBLX dropped after Q2 revenue of $1.47B missed expectations and it withdrew its 2026 outlook. HTZ slid on margin pressure and $11.6B debt. MYGN sank after Q2 revenue of $190.7M missed and it cut its full-year forecast.
4 min readSimply Wall St reports Myriad Genetics (MYGN) shares are down 49% after the company cut its 2026 revenue outlook, citing weakness in prenatal testing. The piece references analyst fair value estimates and highlights potential positive and negative factors for investors, but provides no specific new financial figures beyond the outlook cut.
2 min readSimply Wall St reports Myriad Genetics (MYGN) shares fell nearly 47% in a day after results showed a revenue reset and loss fears. Q2 revenue was $190.7m, down 11% year over year, and full-year 2026 sales guidance was cut to $770m to $790m. Adjusted EBITDA guidance was suspended.
6 min readMyriad Genetics (MYGN) suspended adjusted EBITDA guidance due to uncertainty around initiatives. In Q2 it reported an adjusted EBITDA loss of $16.9M and adjusted loss per share of $0.25. Gross margin fell to 66.6% (66.6% excluding an $11M estimate impact: 68.4%). Liquidity was about $190M. Management cited worsening payer reimbursement friction and launched revenue-cycle and efficiency initiatives.
6 min readMyriad Genetics said it rebuilt its AI document-processing tool, Image Genius, after earlier versions were costly and slow. Working with AWS, it moved the platform to Amazon Bedrock. Myriad reported processing time fell from about 10 minutes to 20 seconds per document and saved about 300 staff hours monthly on ~9,000 prior authorizations. Rollout is planned into 2027.
6 min readMyriad Genetics (MYGN) shares fell 46.1% after the company reported Q2 2026 results that missed Wall Street expectations and cut its full-year forecast. Revenue was $190.7 million, down 10.5% year over year, with an adjusted loss per share of $0.25. Full-year revenue guidance was reduced to a $780 million midpoint.
4 min readMyriad Genetics filed its Form 10-Q for the quarter ended June 30, 2026. The company reported Q2 2026 net loss of $43.2 million, or $0.46 per share, versus $330.5 million in Q2 2025. Total assets fell to $638.9 million and stockholders’ equity to $303.9 million from Dec. 31, 2025. Shares outstanding rose to 95.6 million.
4 min readAnalyst estimates compiled by FactSet show Myriad Genetics’ average 12-month price target cut to $5.75 from $6.14. The range is $4 to $10 per share, implying about 7% upside versus the Jul. 30 close. Consensus remains “Hold” with 2 Buys, 5 Holds, and 2 Sells.
1 min readGenetic testing company Myriad Genetics (NASDAQ: MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million. The company’s full-year revenue guidance of $780 million at the midpoint came in 9.7% below analysts’ estimates. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates. Is now the time to buy Myriad Genetics? Find out by accessing our full research report, it’s free.
4 min readMYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991mygn-xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability Highl ights • Second quarter 2026 revenue of $190.
6 min read
